FGF21 and metabolic dysfunction-associated steatohepatitis: The effect of FGF21 on protecting against NAFLD/NASH is targeted on the pathological characteristics of NAFLD/NASH, including reducing hepatocyte stress and hepatic steatosis as well as directly protecting against inflammation and fibrosis.